Department of Health and Human Services, through National Institutes of Health, awarded Cisterna Biologics, Inc. of Oceanside, CA $350,000 under the SBIR program (Phase I), with work starting 2025-06-05 and running to 2027-05-31. It is one of 2 SBIR and STTR awards Cisterna Biologics, Inc. received in the last two years, $699,746 in all. Each figure links to the federal record.
The award
| Recipient | Cisterna Biologics, Inc. (Oceanside, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $350,000 |
| Period of performance starts | 2025-06-05 |
| Period of performance ends | 2027-05-31 |
| Award number | R41GM159477 (grant, CFDA 93.859) |
| Assistance listing | 93.859, Biomedical Research and Research Training |
| Signed | 2025-06-03 |
| Recipient registry id (UEI) | VGCCUDX8F5P5 |
Want the whole picture on Cisterna Biologics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cisterna Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cisterna Biologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Rapid and ultra-pure MRNA production with next-generation RNA polymerases - project summary cisterna biologics is addressing critical challenges in MRNA purification for therapeutic applications by developing a novel pro
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-03-06 | Revision | 000 | $0 |
| 2025-06-03 | New | 000 | $350,000 |
Rapid and ultra-pure MRNA production with next-generation RNA polymerases - project summary cisterna biologics is addressing critical challenges in MRNA purification for therapeutic applications by developing a novel production and purification process. This Phase I SBIR aims to generate ultra-pure MRNA, essential for high-dosage and frequent administration in treatments ranging from enzyme replacement to cancer immunotherapy. Traditional in vitro transcription (ivt) methods using T7 RNA polymerase produce significant byproducts that can trigger adverse immune responses. In collaboration with the university of texas-austin, cisterna's approach involves the development of cold-adapted (psychrophilic) RNA polymerases (rnaps), which maintain high activity at low temperatures and reduce byproduct formation. Additionally, cisterna's proprietary specific capture and cleavage (specc) purification technology intends to eliminate contaminants completely. The Phase I SBIR project will demonstrate the capability of this technology to synthesize contaminant-free MRNA, improving safety and efficacy for therapeutic use. Initial aims include optimizing psychrophilic rnaps and synthetic promoters to minimize contaminants significantly, with the ultimate goal of replacing current gold-standard purification methods. The successful completion of this phase will pave the way for Phase II, focusing ...
From the federal award record.
Other SBIR and STTR awards to Cisterna Biologics, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-01 | Department of Health and Human Services | SBIR Phase I | $349,746 | A novel approach to eliminate length impurities for high-quality MRNA production - project (record) |
Every other federal award to Cisterna Biologics, Inc. on record
The federal register lists 1 other award to the same registry id (UEI VGCCUDX8F5P5), $274,980 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2024-08-15 | National Science Foundation | $274,980 | SBIR Phase I: Development of a novel platform for cost-efficient MRNA production in yeast -the broader impact (2415711) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Cisterna Biologics, Inc.Look up Cisterna Biologics, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Cisterna Biologics, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.